




USAMRDC Good News Story



U.S. Army Medical Research and Development Command

USAMRIID Scores Win for Public, Force Health with New FDA-Approved Smallpox Vaccine

- U.S. Army scientists played a key role in testing a new smallpox vaccine approved on September 24 by the U.S. Food and Drug Administration.
- The drug, named JYNNEOS, was developed by biotechnology company Bavarian Nordic, and is designed to prevent both smallpox and monkeypox disease.
- As part of the testing effort, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) teamed with the Defense Health Agency (DHA) to lead a Phase 3 clinical trial which ultimately enrolled 440 service members at 65th MED BDE facilities in South Korea.
- Smallpox was officially eradicated in 1980, but since most populations are no longer immunized, a theoretical and intentional release of smallpox virus would have devastating global consequences.



OUTCOME: Smallpox has the potential to be used as biological weapon by enemies of the U.S. This cutting-edge vaccine will have a direct impact on both force health protection and readiness in future operational environments.